Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexpramipexole - Areteia Therapeutics

Drug Profile

Dexpramipexole - Areteia Therapeutics

Alternative Names: BIIB-050; KNS-760704; RPPX

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Virginia
  • Developer Areteia Therapeutics; Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
  • Class Amines; Antiasthmatics; Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Hypereosinophilic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome

Most Recent Events

  • 29 Apr 2024 Areteia Therapeutics initiates enrolment in a phase III EXHALE-5 trial for Asthma (In Adolescents, In Adults, In the elderly) in the US (NCT06388889)
  • 03 Aug 2023 Updated efficacy data from the phase II EXHALE-1 trial in Asthma released by Areteia Therapeutics
  • 27 Mar 2023 Phase-III clinical trials in Asthma (In adolescents, In adults, In the elderly) in Asia (PO) (Areteia Therapeutics website, October 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top